Literature DB >> 2031976

Thalassemia: genotypes and phenotypes.

D Loukopoulos1.   

Abstract

The large degree of phenotypic heterogeneity of thalassemia can now be related to the underlying genomic defects. This information has accumulated rapidly over the last years through the recent advances in molecular technology. The list of main types of thalassemia (alpha or beta) that can be differentiated includes several gene deletions (complete or partial) and point mutations (or very short deletions). These occur within the genes or across the flanking DNA sequences and apparently interfere with the expression of these genes. From a quantitative point of view, the severity of the condition is directly related to the amount of functional globin chain mRNA which is made available to the ribosomes; this may vary from zero (gene deletions, frameshift, non-sense mutations or mutations at the splice-junction nucleotides) to very little (mostly hnRNA processing mutants) or to slightly subnormal (transcriptional mutants, mutations resulting in cryptic site activation or in defective cleavage of the poly-A tail). A few hyper-unstable globin chains also produce a thalassemic phenotype. This pattern is straightforward in the alpha-thalassemias. In the beta-thalassemias, the decreased beta-chain synthesis reflects the available mRNA, but the phenotypic expression depends also on the ability of the patient to reactivate gamma-chain synthesis and complement the red cell content with hemoglobin F.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2031976     DOI: 10.1007/bf01702920

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  46 in total

1.  Recombination at the human alpha-globin gene cluster: sequence features and topological constraints.

Authors:  R D Nicholls; N Fischel-Ghodsian; D R Higgs
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

2.  A novel deletion in the beta-globin gene complex.

Authors:  J S Wainscoat; S L Thein; W G Wood; D J Weatherall; A Metaxotou-Mavromati; S Tzotos; E Kanavakis; C Kattamis
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  The thalassemia repository.

Authors:  A Kutlar; K D Lanclos
Journal:  Hemoglobin       Date:  1987       Impact factor: 0.849

Review 4.  Thalassemia: the consequences of unbalanced hemoglobin synthesis.

Authors:  D G Nathan; R B Gunn
Journal:  Am J Med       Date:  1966-11       Impact factor: 4.965

Review 5.  DNA polymorphism and molecular pathology of the human globin gene clusters.

Authors:  S E Antonarakis; H H Kazazian; S H Orkin
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  The interaction of alpha thalassaemia with heterozygous beta thalassaemia.

Authors:  E Kanavakis; J S Wainscoat; W G Wood; D J Weatherall; A Cao; M Furbetta; R Galanello; D Georgiou; T Sophocleous
Journal:  Br J Haematol       Date:  1982-11       Impact factor: 6.998

7.  A unique thalassaemic syndrome: homozygous alpha-thalassaemia + homozygous beta-thalassaemia.

Authors:  D Loukopoulos; A Loutradi; P Fessas
Journal:  Br J Haematol       Date:  1978-07       Impact factor: 6.998

8.  Abnormal processing of beta Knossos RNA.

Authors:  S H Orkin; S E Antonarakis; D Loukopoulos
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

9.  Lipid membrane peroxidation in beta-thalassemia major.

Authors:  E A Rachmilewitz; S B Shohet; B H Lubin
Journal:  Blood       Date:  1976-03       Impact factor: 22.113

10.  Base substitution in an intervening sequence of a beta+-thalassemic human globin gene.

Authors:  R A Spritz; P Jagadeeswaran; P V Choudary; P A Biro; J T Elder; J K deRiel; J L Manley; M L Gefter; B G Forget; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

View more
  1 in total

1.  Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P W Speiser; J Dupont; D Zhu; J Serrat; M Buegeleisen; M T Tusie-Luna; M Lesser; M I New; P C White
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.